A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

Joyce F. Liu, Niya Xiong, Robert M. Wenham, Andrea E. Wahner Hendrickson, Deborah K. Armstrong, Nancy Chan, David M. O’Malley, Jung Min Lee, Richard T. Penson, Mihaela Cristea, James L. Abbruzzese, Koji Matsuo, Alexander Olawaiye, William T. Barry, Su–Chun Cheng, Madeline Polak, Elizabeth M. Swisher, Geoffrey I. Shapiro, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis